Medicenna Therapeutics (TSE:MDNA) Reaches New 1-Year Low – What’s Next?

Shares of Medicenna Therapeutics Corp. (TSE:MDNA) reached a new 52-week low during trading on Thursday . The company traded as low as C$0.34 and last traded at C$0.35, with a volume of 54128 shares traded. The stock had previously closed at C$0.35.

Medicenna Therapeutics Price Performance

The company has a market capitalization of C$33.23 million, a P/E ratio of -1.64 and a beta of 2.96. The company’s 50-day moving average price is C$0.40 and its two-hundred day moving average price is C$0.62. The company has a debt-to-equity ratio of 4.79, a current ratio of 1.52 and a quick ratio of 4.65.

Medicenna Therapeutics (TSE:MDNA) last posted its earnings results on Thursday, June 25th. The company reported C($0.05) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative return on equity of 219.30% and a negative net margin of 533,640.00%. As a group, sell-side analysts expect that Medicenna Therapeutics Corp. will post -0.37 EPS for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.